The tree · Energy and fuel sensing
A weight-loss drug is approved to prevent heart attacks and strokes in people without diabetes
The GLP-1 drugs (semaglutide, sold as Wegovy and Ozempic, and their successors) copy a gut hormone that tells the body it has eaten, and they act on the same fuel-sensing pathways the ageing field has studied for decades. In 2023 a trial of 17,604 overweight people with heart disease but no diabetes found that semaglutide cut heart attacks, strokes and heart deaths by a fifth over three years, with fewer deaths from any cause. On 8 March 2024 the United States regulator approved it for that purpose, the first time a weight-loss drug was approved to prevent an age-related disease rather than to treat weight. Whether the drugs slow ageing itself is not shown; whether they are the closest thing in wide use to a drug that does is the question the leaf tracks.
What would count
A controlled trial in people without diabetes reports that a GLP-1 drug lowers death from any cause, or heart attacks and strokes, more than placebo, in a peer-reviewed report. For the clinic rung: a regulator approves such a drug to prevent an age-related disease, rather than to treat weight or blood sugar. For wide use: the drug is available by prescription for that purpose in several countries and taken by a substantial share of eligible people.
Who settles it: The peer-reviewed trial report; the regulator's approval record; published uptake figures for the wide-use rung.
Where it stands
In clinical use. Reached 8 March 2024, on the record of fda.gov. Next rung within 1 to 5 years. The year the model reads for it is 2024, the year it reached the clinic; what has happened is not drawn.
When it reaches the clinic: the project's estimate
This is the one thing on this page that is a judgment rather than a record. It is already in the clinic, so the model reads a known year; the estimate below is for the rungs still above it and feeds nothing. Set 16 October 2026, a first pass awaiting an outside review.
| Rung | No earlier than | Most likely | No later than | |
|---|---|---|---|---|
| In wide use | 2027 | 2029 | 2040 |
Why. The drugs are taken by tens of millions of people and prices were falling as pills and copies arrived; the likely year for wide use on the heart-prevention indication is 2029, the earliest allows that it is already met once uptake is counted, and the latest allows for the indication staying a label line that few prescribers use. [Note 2026-10-17, from the weekly reading of that date: the first published uptake figure for this purpose (scannell-2026) is under 1 per cent of eligible Medicare beneficiaries six months after coverage began, with data to September 2024. That points the other way from the earliest year of 2027 above, which assumed uptake might already count. The years are unchanged; John may want to weigh moving the earliest wide-use year later at the next review.]
Changes to this record
- 17 October 2026, notes: (nothing; text added at the end of the notes) became Added 2026-10-17, from the weekly reading of that date: the first published uptake figure for the heart-prevention purpose is a study in the American Journal of Managed Care (scannell-2026, 2026-07-09), using national prescription counts to September 2024. Wegovy fills rose 136 per cent after the approval of 2024-03-08 and Medicare coverage, yet six months after Medicare plans began covering it only 32,732 prescriptions had been filled, under 1 per cent of an estimated 3.6 million eligible beneficiaries. It is one country and one payer, and the data end in September 2024. It does not change the stage.. [reading 2026-10-17] Records the first published uptake figure, which the notes said was still to come. Source: Scannell and 4 others, 9 July 2026.
- 17 October 2026, estimate.why: (nothing; a dated note added at the end of the reasoning; no year changed) became [Note 2026-10-17, from the weekly reading of that date: the first published uptake figure for this purpose (scannell-2026) is under 1 per cent of eligible Medicare beneficiaries six months after coverage began, with data to September 2024. That points the other way from the earliest year of 2027 above, which assumed uptake might already count. The years are unchanged; John may want to weigh moving the earliest wide-use year later at the next review.]. [reading 2026-10-17] A dated note that the first uptake figure undercuts the premise behind the earliest wide-use year; no year changed. Source: Scannell and 4 others, 9 July 2026.
The last readings
- 17 October 2026 Left for the author
Nothing in the window: no new approval, trial report or uptake figure dated 2026-10-10 to 2026-10-17 was found, and the company's newsroom could not be opened from this session. One older record bears on the wide-use test and the record does not name it: a study by Scannell and colleagues published in The American Journal of Managed Care on 2026-07-09, using IQVIA prescription data from September 2023 to September 2024, found that the heart-prevention approval of 2024-03-08 and the Medicare coverage that followed were associated with about 592,624 extra Wegovy fills, a 136 per cent rise, yet six months after the Medicare announcement fewer than one per cent of the roughly 3.6 million Medicare beneficiaries estimated to be eligible on weight and heart grounds had filled a Wegovy prescription. Five searches were run for this leaf, one over the brief's cap, because the first four found nothing on uptake; all five are listed. Left for the author, resolved on 17 October 2026: The settler names published uptake figures for the wide-use rung, and the notes say the rung stays at clinical use until uptake figures for the heart-prevention purpose are in hand. This 2026-07-09 study is such a figure, and it points the other way from the estimate's earliest year of 2027: under one per cent of eligible Medicare beneficiaries in the first six months, in one country and one payer, with data ending September 2024. I would add it to the publications log, cite it in the leaf's notes as the first uptake figure on record, and consider whether the earliest year for wide use should move later. It is dated before the window and bears on the estimate rather than the stage, so it is the author's call; and the article's own page could not be opened, so the citation below is from search summaries only. To log in the publications log once its page has been read, as the reading's rule asks: Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies (The American Journal of Managed Care (2026), 2026-07-09; https://www.ajmc.com/view/changes-in-semaglutide-fills-following-expanded-fda-and-medicare-policies).source 1, source 2, source 3, source 4
What the story so far says about it
On the record
- 9 July 2026Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
- 11 November 2023Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Notes
Semaglutide for weight loss alone is in wide use by any measure; the leaf's test is narrower, the approval to prevent an age-related disease, and the record keeps that rung at clinical use until uptake figures for that purpose are in hand. The drugs' effect on measures of biological age was being studied when this was written and has no peer-reviewed result; if one comes it belongs on the measuring branch's clock-slowing leaf, not here. Added 2026-10-17, from the weekly reading of that date: the first published uptake figure for the heart-prevention purpose is a study in the American Journal of Managed Care (scannell-2026, 2026-07-09), using national prescription counts to September 2024. Wegovy fills rose 136 per cent after the approval of 2024-03-08 and Medicare coverage, yet six months after Medicare plans began covering it only 32,732 prescriptions had been filled, under 1 per cent of an estimated 3.6 million eligible beneficiaries. It is one country and one payer, and the data end in September 2024. It does not change the stage.
Not yet verified
These facts in the record were written from memory or from a secondary source and have not yet been checked against the paper, the regulator's record or the registry. Nothing here is presented as settled until it is cleared, by checking it and either deleting the line or correcting the record.
- No animal rung is recorded: a Nature report of 2026-09-02 shows late-life semaglutide lengthened the median life of female mice, but it came after the drug's approval and is a lifespan result, not a heart-event result, so it was not entered as an earlier stage.